WO2001038318A1 - Cytotoxic agents comprising taxanes and their therapeutic use - Google Patents
Cytotoxic agents comprising taxanes and their therapeutic use Download PDFInfo
- Publication number
- WO2001038318A1 WO2001038318A1 PCT/US2000/030149 US0030149W WO0138318A1 WO 2001038318 A1 WO2001038318 A1 WO 2001038318A1 US 0030149 W US0030149 W US 0030149W WO 0138318 A1 WO0138318 A1 WO 0138318A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- branched
- linear
- same
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to novel cytotoxic agents and their therapeutic use. More specifically, the invention relates to novel cytotoxic agents comprising taxanes and their therapeutic use. These novel cytotoxic agents have therapeutic use as a result of delivering the taxanes to a specific cell population in a targeted fashion by chemically linking the taxane to a cell binding agent.
- Cytotoxic drugs such as methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, melphalan, mitomycin C, and chlorambucil have been conjugated to a variety of murine monoclonal antibodies.
- the drug molecules were linked to the antibody molecules through an intermediary carrier molecule such as serum albumin (Garnett et al, 46 Cancer Res. 2407-2412 (1986); Ohkawa et al 23 Cancer Immunol. Immunother. 81-86 (1986); Endo et al, 47 Cancer Res. 1076-1080 (1980)), dextran (Hurwitz et al, 2 Appl Biochem. 25-35 (1980); Manabi et al, 34
- antibody-drug conjugates is an acid-labile linker based on c.s-aconitic acid that takes
- daunorubicin with macromolecular carriers 102 Biochem. Biophys. Res. Commun.
- cancerostatic drugs like methotrexate, daunorubicin, and vincristine.
- CC-1065 have also been reported (USP 5,475,092 and USP 5,585,499).
- Paclitaxel (Taxol), a cytotoxic natural product, and docetaxel (Taxotere), a
- Taxanes are a grouping of compounds that are structurally similar to compounds called taxanes. These compounds belong to the family of compounds called taxanes . Taxanes are a grouping of compounds that are structurally similar to compounds called taxanes .
- paclitaxel are useful agents in the treatment of cancer, their antitumor activity is limited because of their non-specific toxicity towards normal cells. Further, compounds like paclitaxel and docetaxel themselves are not sufficiently potent to be used in conjugates of cell binding agents. Recently, a few new docetaxel analogs with greater potency than either docetaxel or paclitaxel have been described (Iwao Ojima et al., J. Med. Chem. 39, 3889-3896 (1996) and Figure 1). However, these compounds lack a suitable functionality that allows linkage via a cleavable bond to cell binding agents.
- One object of the present invention is to provide taxanes that are highly toxic and that can still be effectively used in the treatment of many diseases.
- Another object of the present invention is to provide novel taxanes.
- cytotoxic agent comprising one or more taxanes linked to a cell binding agent.
- the present invention provides a therapeutic composition comprising:
- the present invention provides a method of killing selected cell populations comprising contacting target cells or tissue containing target cells, with a cytotoxic amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent.
- the present invention provides taxanes comprising a linking group capable of linking said taxanes to a cell binding agent or other chemical 5 moieties.
- Figure 1 is a chemical formula that represents structures of various taxanes, including some of the more potent taxanes described by Ojima et al., supra.
- Figure 2 is a chemical formula that represents structures of some of the o disulfide-containing taxanes according to the present invention.
- Figure 3 shows the structure of 10-deacetylbaccatin HI, which is the starting material for preparing taxanes.
- Figure 4 shows the anti-tumor effect of anti-EGF Receptor Antibody-Taxane Conjugate on human squamous cancer (A431) xenografts in SCID mice.
- Figure 5 shows the body weight change of the SCID mice used in the experiment described in Example 10.
- Figure 6 shows the results of a cytotoxicity determination for the anti-EGF receptor-tax ane conjugate on the target antigen-positive cell line A431 and for the N901-taxane conjugate for which the A431 cell line does not express the target o antigen.
- Figure 7 shows the cytotoxic potency and selectivity of the TA.l-taxane conjugate in the target antigen-positive cell line SK-BR-3 and the target antigen-negative cell line A431.
- This invention is based on the synthesis of novel taxanes that retain high
- conjugates are cytotoxic in an antigen specific manner (R.V.J. Chari et al, 52
- the disclosed invention overcomes this problem by modifying the
- taxanes with chemical moieties and especially ones containing thiol or
- This invention permits the taxanes to be target site-directed which had
- the invention provides useful agents for the
- the cytotoxic agent according to the present invention comprises one or more taxanes linked to a cell binding agent via a linking group.
- the linking group is part of a chemical moiety that is covalently bound to a taxane through conventional methods.
- the chemical moiety can be covalently bound to the taxane via an ether linkage.
- taxanes useful in the present invention have the formula (I) shown below:
- Ri is an electron withdrawing group, such as F, NO ,
- R 7 and R 8 are the same or different and are linear, branched, or cyclic alkyl groups having 1 to 10 carbon atoms or simple or substituted aryl having 1 to 10 carbon atoms. Preferably the number of carbon atoms for R 7 and R 8 is 1 to 4. Also, preferably R 7 and R 8 are the same.
- R 8 groups include dimethyl amino, diethyl amino, dipropyl amino, and dibutyl amino, where the butyl moiety is any of primary, secondary, tertiary or isobutyl.
- R 9 is linear, branched or cyclic alkyl having 1 to 10 carbon atoms.
- R] is preferably F, NO 2 , or CF 3 .
- R] is in the eta position and Ri' and Ri" are H.
- R 2 is heterocyclic, a linear, branched, or cyclic ester or ether having from 1 to 10 carbon atoms or a carbamate of the formula
- R ]0 and Rn are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms.
- R ]0 and Rn are the same or different and are H, linear, branched, or cyclic alkyl having 1 to 10 atoms or simple or substituted aryl having 1 to 10 carbon atoms.
- preferred examples include -COCH 2 CH 3 and -COCH 2 CH 2 CH 3 .
- preferred examples include -CONHCH 2 CH 3> -CONHCH 2 CH 2 CH 3 , -CO-morpholino, -CO-piperazino, -CO-piperidino, or -CO-N-methylpiperazino.
- R 2 is the linking group.
- R 3 is aryl, or is linear, branched or cyclic alkyl having 1 to 10 carbon atoms, preferably -CH 2 CH(CH 3 ) 2 .
- R4 is -OC(CH 3 ) 3 or -C 6 H5.
- R is the linking group and R 6 is H or has the same definition as above for R 2 for embodiments (1), (2) and (4).
- R 5 is H or has the same definition as above for R 2 for embodiments (1), (2) and (4).
- R 6 is H or has the same definition as above for R 2 for embodiments (1), (2) and (4).
- R 5 is H or has the same definition as above for R 2 for embodiments (1), (2) and (4) and R 6 is a linking group.
- linking group The preferred positions for introduction of the linking group are R 2 and R 5 , with R 2 being the most preferred.
- Suitable linking groups are well known in the art and include disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile groups and esterase labile groups. Preferred are disulfide groups and thioether groups.
- the side chain carrying the thiol or disulfide group can be linear or branched, aromatic or heterocyclic.
- the thiol- or disulfide- containing substituents include -(CH ) n SZ,
- Z is H or SR
- X is a linear alkyl or branched alkyl having 1-10 carbon atoms.
- R and R ⁇ 2 are the same or different and are linear alkyl, branched alkyl or cyclic alkyl having 1 to 10 carbon atoms, or simple or substituted aryl having from 1 to 10 carbon atoms or heterocyclic, and R] can in addition be H, and
- n is an integer of 1 to 10.
- linear alkyls examples include methyl, ethyl, propyl, butyl, pentyl and hexyl.
- branched alkyls examples include isopropyl, isobutyl, sec. -butyl, tert.-butyl, isopentyl and 1-ethyl-propyl.
- cyclic alkyls examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- Examples of simple aryls include phenyl and naphthyl.
- substituted aryls include aryls such as those described above substituted with alkyl groups, with halogens, such as Cl, Br, F, nitro groups, amino groups, sulfonic acid groups, carboxyhc acid groups, hydroxy groups or alkoxy groups.
- heterocyclics are compounds wherein the heteroatoms are selected from O, N, and S, and include mo ⁇ holino, piperidino, piperazino, N-methylpiperazino, pyrrollyl, pyridyl, furyl and thiophene.
- taxanes of the present invention that have a thiol- or disulfide-containing substituent are in themselves novel.
- the taxanes that have a thiol or disulfide-containing substituent can be synthesized according to known methods.
- the starting material for the synthesis is the commercially available 10-deacetylbaccatin HI, shown in Figure 3.
- the chemistry to introduce various substituents is described in several publications (Ojima et al, J.Med. Chem.39, 3889-3896, (1996), Ojima et al., 40 J. Med. Chem. 267-278 (1997); I. Ojima et al., 96 Proc. Natl Acad. Sci, 4256-4261 (1999); I. Ojima et al., USP 5,475,011 and USP 5,811,452.).
- the substituent Ri on the phenyl ring and the position of the substituent Ri can be varied until a compound of the desired toxicity is obtained. Furthermore, the degree of substitution on the phenyl ring can be varied to achieve a desired toxicity. That is, the phenyl ring can have one or more substituents (e.g., mono-, di-, or tri -substitution of the phenyl ring) which provide another means for achieving a desired toxicity.
- High cytotoxicity is defined as exhibiting a toxicity having an IC 5 o in the range of 1 x 10 "12 to 3 x 10 " M, when measured in vitro with cultured cancer cells upon a 72 hour exposure time to the drug.
- One of ordinary skill in the art can determine the appropriate chemical moiety for R and the appropriate position for R ⁇ using only routine experimentation.
- the disulfide or thiol-containing substituent can be introduced at one of the positions where a hydroxyl group already exists.
- the chemistry to protect the various hydroxyl groups, while reacting the desired one, has been described previously (see, for example, the references cited supra).
- the substituent is introduced by simply converting the free hydroxyl group to a disulfide-containing ether, a disulfide-containing ester, or a disulfide-containing carbamate. This transformation is achieved as follows.
- the desired hydroxyl group is deprotonated by treatment with the commercially available reagent lithium hexamethyldisilazane (1.2 equivalents) in tetrahydrofuran at -40°C as described
- the desired hydroxyl group can be esterified directly by reaction
- acyl halide such as 3-bromopropionyl chloride
- amino alkyl disulfide e. g., methyldithio cysteamine
- Disulfide-containing and thiol-containing taxane drugs of the invention can be
- cell lines such as the human epidermoid carcinoma line A431, the human
- breast tumor line SKBR3 and the Burkitt's lymphoma line Namalwa can easily be used
- Cells to be evaluated can be assessed for the assessment of cytotoxicity of these compounds.
- Cells to be evaluated can be assessed for the assessment of cytotoxicity of these compounds.
- IC 50 values can then be calculated from the results of the assays.
- agents may be of any kind presently known, or that become known and include peptides
- these can be antibodies, or fragments thereof, (especially monoclonal antibodies), lymphokines, hormones, growth factors, vitamins,
- nutrient-transport molecules such as transferrin
- any other cell binding molecule such as transferrin
- cell binding agents that can be used include:
- -interferons e.g. ⁇ , ⁇ , ⁇
- -lymphokines such as IL-2, IL-3, IL-4, EL-6;
- -hormones such as insulin, TRH (thyrotropin releasing hormones), MSH
- melanocyte-stimulating hormone steroid hormones, such as androgens and estrogens
- -vitamins such as folic acid
- EGF EGF
- TGF- ⁇ TGF- ⁇
- G-CSF G-CSF
- Monoclonal antibody techniques allow for the production of extremely specific cell binding agents in the form of specific monoclonal antibodies or fragments thereof.
- Particularly well known in the art are techniques for creating monoclonal antibodies, or fragments thereof, by immunizing mice, rats, hamsters, or any other mammal with the antigen of interest such as the intact target cell, antigens isolated from the target cell, 5 whole virus, attenuated whole virus, and viral proteins such as viral coat proteins.
- Sensitized human cells can also be used.
- Another method of creating monoclonal antibodies, or fragments thereof, is the use of phage libraries of sFv (single chain variable region), specifically human sFv. (See e.g., Griffiths et al., USP 5,885,793; McCafferty et al., WO 92/01047; Liming et al., WO 99/06587.)
- the monoclonal antibody J 5 is a murine IgG 2a antibody that is specific for Common Acute Lymphoblastic Leukemia Antigen (CALLA) (Ritz et al, 283 5 Nature 583-585 (1980)) and can be used if the target cells express CALLA such as in the disease of acute lymphoblastic leukemia.
- the monoclonal antibody anti-B4 is a murine IgGi, that binds to the CD19 antigen on B cells (Nadler et al, 131 J. Immunol. 244-250 (1983)) and can be used if the target cells are B cells or diseased cells that express this antigen such as in non-Hodgkin's lymphoma or chronic lymphoblastic
- GM-CSF which binds to myeloid cells can be used as a cell binding agent to diseased cells from acute myelogenous leukemia.
- IL-2 which binds to activated T-cells can be used for prevention of transplant graft rejection, for therapy and prevention of graft- versus-host disease, and for treatment of acute T-cell leukemia.
- MSH which binds to melanocytes can be used for the treatment of melanoma.
- estrogen analogues or androgen (or androgen analogues) respectively as cell binding
- Conjugates of the taxanes of the invention and a cell binding agent can be
- the taxane ester can be condensed
- the hydroxyl group on the taxane ester can be succinylated and linked to a
- taxane ethers, esters, or carbamates are treated to
- conjugates of the invention are antibody-taxane, antibody-
- EGF epidermal growth factor
- MSH thyroid stimulating hormone
- TSH thyroid stimulating hormone
- estrogen-taxane estrogen-taxane
- estrogen analogue-taxane androgen-taxane, androgen analogue-taxane, and folate-
- Taxane conjugates of antibodies, antibody fragments, protein or peptide hormones, protein or peptide growth factors and other proteins are made in the same way
- peptides and antibodies can be modified with cross
- linking reagents such as N-succinimidyl 3-(2-pyridyldithio)propionate, N-succinimidyl
- SDPB ⁇ -succinimidyl-3-(2-pyridyldithio) butyrate
- 2-iminothiolane 2-iminothiolane
- conjugates can be purified by HPLC or by gel filtration.
- estrogen and androgen cell binding agents such as
- estradiol and androstenediol can be esterified at the C-17 hydroxy group with an
- estrogen can then be reacted with a disulfide- or thiol-containing taxane to produce
- conjugates can be purified by column chromatography on silica gel or
- disulfide-containing folate can then be reacted with a thiol-containing taxane to produce
- monoclonal antibody- or cell binding agent-taxane conjugates are provided.
- SPDP dithiopropionate
- disulfide bridge are readily prepared by either method.
- thiopyridine is treated with the thiol-containing taxane (1.25 molar eq./ dithiopyridyl group). The release of thiopyridine from the modified antibody is
- antibody-taxane conjugate is purified and freed of unreacted drug and other low
- molecular weight material by gel filtration through a column of Sephadex G-25 or Sephacryl S300.
- the number of taxane moieties bound per antibody molecule can be
- Antibody-taxane conjugates with non-cleavable links can also be prepared.
- antibody can be modified with crosslinking reagents such as succinimidyl
- SMCC 4-(maleimidomethyl)cyclohexane-l -carboxylate
- sulfo-SMCC 4-(maleimidomethyl)cyclohexane-l -carboxylate
- MBS m-maleimidobenzoyl-N-hydroxysuccinimide ester
- Sulfo-MBS sulfo-MBS
- succinimidyl-iodoacetate as described in the literature, to introduce 1-10 reactive
- modified antibody is then reacted with the thiol-containing taxane derivative to produce
- the conjugate can be purified by gel filtration through a Sephadex G-25
- modified antibodies, or fragments thereof, are treated with the amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids
- a preferred method is to modify antibodies, or fragments thereof, with
- succinimidyl-4-(maleimidomethyl)-cyclohexane-l -carboxylate (SMCC) to introduce
- A431 can be determined by clonogenic assays as described in Goldmacher et al, 102 J.
- the present invention also provides a therapeutic composition comprising:
- the present invention provides a method for killing selected cell
- populations comprising contacting target cells or tissue containing target cells with an
- the cytotoxic agent is prepared as described above.
- Suitable pharmaceutically acceptable carriers, diluents, and excipients are well
- Suitable carriers, diluents and or excipients include: (1) Dulbecco's
- dextrose may also contain an antioxidant such as tryptamine and a stabilizing agent
- the method for killing selected cell populations can be practiced in vitro, in vivo,
- in vitro uses include treatments of autologous bone marrow prior to
- graft-versus-host-disease GVHD
- Examples of clinical ex vivo use are to remove tumor cells or lymphoid cells
- Treatment can be carried out as follows. Bone marrow is harvested from the patient or
- concentrations range from about 10 ⁇ M to 1 pM, for
- the treated marrow cells are stored frozen in liquid
- the cytotoxic agent of the invention will be supplied as a
- Dosages will be 10 ⁇ g to 2000 mg per administration, intravenously (range of
- administration, excipients, diluents, dosages, times, etc. can be determined by one of
- vivo methods of killing selected cell populations include malignancy of any type
- cancers including, for example, cancer of the lung, breast, colon, prostate, kidney, pancreas,
- autoimmune diseases such as systemic lupus, rheumatoid arthritis, and multiple sclerosis
- graft rejections such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection
- graft versus host disease viral infections, such as CMV infection, HTV infection, ADDS, etc.
- parasite infections such as giardiasis, 5 amoebiasis, schistosomiasis, and others as determined by one of ordinary skill in the art.
- the sulfide, disulfide, and sulfhydryl containing taxane drugs of the invention can be evaluated for their ability to suppress proliferation of various human tumor cell lines in vitro.
- Two adherent cell lines A431 (human epidermoid carcinoma) and SKBR3 (human breast tumor) and the non-adherent cell line, Namalwa (Burkitt's lymphoma) are 5 used for the assessment of cytotoxicity of these compounds. Cells are exposed to the compounds for 24 hours and the surviving fractions of cells are measured in direct assays. (A431 and SKBR3 are assayed for plating efficiency (Goldmacher et al, 102 J. Cell. Biol.
- succinimidyl pyridyldithiopentanoate SPP
- Antibodies anti-B4, anti-EGF Preparation of Antibody-SS-Taxane Conjugates.
- Antibodies anti-B4, anti-EGF Antibodies anti-B4, anti-EGF
- N901, or fragments thereof are modified with SPDP or SPP as described in
- antibody-taxane conjugate is purified and freed of unreacted drug and other low
- the antibody, or fragment thereof, is first reacted with succinimidyl
- SMCC maleimidomethylcyclohexane carboxylate
- modified antibody is then reacted with the thiol-containing taxane forming thioether
- anti-B4, anti-EGF receptor and N901, or fragments thereof are modified with SMCC as
- modified antibodies or antibody fragments are treated with thiol-containing
- the antibody-taxane conjugates are purified as described above. Typically, an
- Murine monoclonal antibodies directed against the human EGF receptor are Murine monoclonal antibodies directed against the human EGF receptor
- EGF EGF receptor
- human squamous cell cancers such as, head and neck, lung and breast.
- KS-61 IgG2a
- KS-77 IgGl
- KS-78 Ig2a
- KS-62 IgG2a
- the anti -EGFR antibody KS-61 was first modified with N-succinimidyl-4-[2-pyridyldithio] pentanoate (SPP) to introduce dithiopyridyl groups.
- SPP N-succinimidyl-4-[2-pyridyldithio] pentanoate
- the antibody (2.3 mg/mL) in 50 mM potassium phosphate buffer, pH 6.5, containing NaCl (50 mM) and EDTA (2 mM), was treated with SPP (11 molar equivalents in ethanol). The final ethanol concentration was 1.4% (v/v). After 90 minutes at ambient temperature, lysine (50 mM) was added to help in the removal of any non-covalently bound SPP.
- the reaction was allowed to proceed for two hours, and then purified by gel filtration through a Sephadex G25 column equilibrated in the above buffer. Antibody-containing fractions were pooled and the degree of modification was determined by treating a sample with dithiothreitol and measuring
- the modified antibody was diluted with 50 mM potassium phosphate buffer,
- Taxane-SH (1.7 eq. per dithiopyridyl group) in ethanol (10 % v/v in final
- reaction mixture was then added to the modified antibody solution.
- the reaction mixture was then added to the modified antibody solution.
- the conjugate was formulated with Tween 80
- HSA human serum albumin
- the anti-EGFR antibody KS-77 was modified with
- the antibody (5.0 mg/mL) in 50 mM potassium phosphate buffer, pH 6.5,
- reaction mixture was allowed to incubate for two hours, and then purified by gel
- antibody was about 90%, with 4.24 pyridyldithio groups linked per antibody
- the modified antibody was diluted with 50 mM potassium phosphate buffer, pH 6.5, containing NaCl (50 mM) and EDTA (2 mM) to a final concentration of 1.4
- Taxane-SH (1.7 equivalents per dithiopyridyl group) in ethanol (10 % v/v in
- the major peak comprised monomeric KS-77-Taxane.
- concentration of antibody KS-77 was determined by measuring the absorbance at 280
- the conjugate was formulated with Tween 80 (0.06%) and HSA (1 mg/mL).
- the anti-EGF antibody-taxane conjugate (KS-62-Taxane) was prepared in a
- the major peak comprised monomeric KS-62-Taxane.
- the conjugate was
- the anti-EGFR antibody-Taxane conjugate, KS-78-Taxane, was prepared in a
- Taxane-SH isobutyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the murine monoclonal antibody TAl which binds to the neu oncogene
- reaction mixture was incubated for 2 hours, and
- Antibody-containing fractions were pooled and the degree of modification was
- the modified antibody was diluted with 50 mM potassium phosphate buffer,
- Taxane-SH (1.7 eq. per pyridyldithio group inco ⁇ orated) in ethanol (10 %
- the conjugates were formulated in PBS containing Tween 80 (0.01%) and HSA (1 mg/mL).
- Taxanes can be esterified with N-protected amino acids, such as
- DMAP dimethylaminopyridine
- taxane ester containing a terminal amino group This amino group containing taxane can
- amino group-containing taxane described above can also be linked to cell
- the amino group containing taxane can be condensed with peptides such as Ala-Leu, Leu- Ala-Leu or a dimer of Ala-Leu using
- condensing agents such as l-[3-(dimethylamino)propyl]-3-ethyl carbodiimide-HCl to
- Taxanes can be esterified by reaction of the hydroxyl group with succinic
- KS-77-Taxane was evaluated in a human tumor xeno J ogr'aft model in SCID mice.
- the first group received KS-61-Taxane conjugate (10 mg/kg, qd x 5) administered intravenously.
- the second group received the KS-77-Taxane conjugate (10 mg/kg, qd x 5) administered intravenously.
- the third group received free (non- conjugated) taxane (0.24 mg/kg, qd x 5, intravenously) at the same dose as that present in the conjugate.
- the fourth group, a control group, of animals received PBS using the same treatment schedule as in groups 1-3.
- the sizes of the tumors were measured twice weekly and the tumor volumes were calculated with the formula: 2 (length x width x height). The weight of the animals was also measured twice per week. The results are shown in Figures 4 and 5.
- the tumors in the control group of mice grew to a size of nearly 1000 mm 3 in 31 days. Treatment with free taxane showed no therapeutic effect, and the tumors in this group grew at essentially the same rate as in the control group of animals that received PBS.
- both of the anti-EGFR-taxane conjugates showed remarkable antitumor activity resulting in complete inhibition of tumor growth in all the treated animals for the duration of the experiment— 34 days for the KS-61 -Taxane conjugate and 27 days for the KS-77-Taxane conjugate.
- the data also show that targeted delivery of the taxane using a tumor-specific antibody is essential for the anti-tumor activity, since an equivalent dose of unconjugated taxane showed no anti-tumor effect in this model.
- the doses of antibody-taxane conjugate used were non- toxic to the animals as demonstrated by the absence of any weight loss (see Figure 5).
- N901-taxane conjugate a similar conjugate made with the mouse monoclonal N901 antibody against human CD56 was tested as a specificity
- TA. l -Taxane conjugate a conjugate made with the mouse monoclonal antibody TA.l
- SK-BR-3 ATCC HTB 30
- antigen-negative A431 cell line Cells were plated at different densities in 6-well tissue-culture plates in DMEM medium supplemented
- fractions of cells were calculated as the ratio of the plating efficiency of the treated
- Figure 6 shows the results of the cytotoxicity determination for the two
- Conjugates from both batches show similar toxicity to the target cells; treatment for 6 days at concentrations of 10 "8 M achieved surviving fractions of less than 10 "2 (less than 1 % of cells survive).
- a control conjugate, N901 -Taxane, for which there are no antigens present on the surface of A431 cells shows no toxicity to the cells at concentrations of up to 3 x 10 " M.
- Unconjugated KS-78 antibody also shows very little cytotoxic effect.
- the cytotoxic potency and selectivity of the TA.l-taxane conjugate was assayed with the target antigen-positive cell line SK-BR-3 and the target antigen-negative cell line A431. The results are shown in Figure 7. At a conjugate concentration of 10 "9 M, more than 90 % of the target SK-BR-3 cells were killed
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU19149/01A AU765588C (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
DE60032633T DE60032633T2 (en) | 1999-11-24 | 2000-11-21 | CYTOTOXIC AGENTS CONTAINING TAXANE AND ITS THERAPEUTIC APPLICATION |
DK00982077T DK1242401T3 (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
CA2388063A CA2388063C (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
EP00982077A EP1242401B1 (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
JP2001540081A JP2003514903A (en) | 1999-11-24 | 2000-11-21 | Taxane-containing cytotoxic drugs and their therapeutic use |
NZ517772A NZ517772A (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
HK03101738.2A HK1049997B (en) | 1999-11-24 | 2003-03-11 | Cytotoxic agents comprising taxanes and their therapeutic use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16722899P | 1999-11-24 | 1999-11-24 | |
US60/167,228 | 1999-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001038318A1 true WO2001038318A1 (en) | 2001-05-31 |
Family
ID=22606479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/030149 WO2001038318A1 (en) | 1999-11-24 | 2000-11-21 | Cytotoxic agents comprising taxanes and their therapeutic use |
Country Status (13)
Country | Link |
---|---|
US (11) | US6340701B1 (en) |
EP (1) | EP1242401B1 (en) |
JP (1) | JP2003514903A (en) |
AT (1) | ATE349438T1 (en) |
AU (1) | AU765588C (en) |
CA (1) | CA2388063C (en) |
DE (1) | DE60032633T2 (en) |
DK (1) | DK1242401T3 (en) |
ES (1) | ES2276708T3 (en) |
HK (1) | HK1049997B (en) |
NZ (1) | NZ517772A (en) |
PT (1) | PT1242401E (en) |
WO (1) | WO2001038318A1 (en) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049672A2 (en) * | 2000-12-21 | 2002-06-27 | Mcgill University | Conjugates of antibodies and anticancer drugs |
EP1534674A2 (en) * | 2002-08-02 | 2005-06-01 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
JP2005533026A (en) * | 2002-05-14 | 2005-11-04 | イミュノジェン・インコーポレーテッド | Cytotoxic agent containing taxane containing polyethylene glycol and therapeutic use thereof |
JP2006500364A (en) * | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | Crosslinkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
EP1669358A1 (en) * | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
WO2006061259A2 (en) * | 2004-12-07 | 2006-06-15 | Aventis Pharma S.A. | Cytotoxic agents comprising new c-2 modified taxanes |
EP1718335A2 (en) * | 2004-02-12 | 2006-11-08 | The Research Foundation Of State University Of New York | Drug conjugates |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
US7374762B2 (en) | 2003-05-14 | 2008-05-20 | Immunogen, Inc. | Drug conjugate composition |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
EP2241577A1 (en) | 2007-08-09 | 2010-10-20 | Boehringer Ingelheim International GmbH | Anti-CD37 antibodies |
WO2010141566A1 (en) | 2009-06-03 | 2010-12-09 | Immunogen, Inc. | Conjugation methods |
EP2278963A2 (en) * | 2008-01-16 | 2011-02-02 | Anwar Rayan | Derivatives of taxol and closely related compounds |
EP2384767A1 (en) | 2005-03-24 | 2011-11-09 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
WO2013160396A1 (en) | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
WO2013171287A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
WO2013171289A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with further agents |
WO2013184514A1 (en) | 2012-06-04 | 2013-12-12 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
US8617554B2 (en) | 2009-05-13 | 2013-12-31 | Genzyme Corporation | Anti-human CD52 immunoglobulins |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
WO2014124316A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
WO2014151644A2 (en) | 2013-03-15 | 2014-09-25 | Genzyme Corporation | Anti-cd52 antibodies |
WO2014160160A2 (en) | 2013-03-13 | 2014-10-02 | Novartis Ag | Antibody drug conjugates |
US9114179B2 (en) | 2005-08-03 | 2015-08-25 | Immunogen, Inc. | Immunoconjugate formulations |
WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
WO2015138615A2 (en) | 2014-03-12 | 2015-09-17 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
WO2016203432A1 (en) | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
EP3266469A2 (en) | 2008-04-30 | 2018-01-10 | ImmunoGen, Inc. | Cross-linkers and their uses |
WO2018142322A1 (en) | 2017-02-03 | 2018-08-09 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
WO2019016772A2 (en) | 2017-07-21 | 2019-01-24 | Novartis Ag | Compositions and methods to treat cancer |
US10232051B2 (en) | 2015-07-15 | 2019-03-19 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
EP3514178A1 (en) | 2013-03-15 | 2019-07-24 | Novartis AG | Antibody drug conjugates |
EP3520816A2 (en) | 2009-10-23 | 2019-08-07 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
WO2020075817A1 (en) | 2018-10-10 | 2020-04-16 | 武田薬品工業株式会社 | Method for manufacturing antibody-drug conjugate |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
WO2020128612A2 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Antibodies to pmel17 and conjugates thereof |
EP3888691A1 (en) | 2016-11-14 | 2021-10-06 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
WO2021220199A1 (en) | 2020-04-30 | 2021-11-04 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
WO2022112942A2 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
WO2022221720A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
CA2362937C (en) * | 1999-02-24 | 2011-03-22 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
JP4776843B2 (en) * | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | Cancer composition and method using immunoconjugate and chemotherapeutic agent |
JP2003514903A (en) * | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | Taxane-containing cytotoxic drugs and their therapeutic use |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
EP1318794A2 (en) * | 2000-09-22 | 2003-06-18 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
WO2002076394A2 (en) * | 2001-03-22 | 2002-10-03 | The Ohio State University Research Foundation | Enzyme-based anti-cancer compositions and methods |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
PT1392359E (en) | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and uses thereof |
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
JP4619651B2 (en) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Modified antibodies against prostate-specific membrane antigen and uses thereof |
US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
EP1552002A4 (en) * | 2002-06-18 | 2006-02-08 | Archemix Corp | Aptamer-toxin molecules and methods for using same |
US7202346B2 (en) * | 2002-07-03 | 2007-04-10 | Immunogen Inc. | Antibodies to non-shed Muc1 and Muc16, and uses thereof |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7834155B2 (en) * | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
CA2532430C (en) * | 2003-07-21 | 2016-12-13 | Immunogen, Inc. | Humanized versions of monoclonal antibody ds6 that bind tumour antigen ca6 |
WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
AU2004224925C1 (en) * | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
JP5165387B2 (en) | 2005-02-11 | 2013-03-21 | イムノゲン インコーポレーティッド | Method for preparing stable drug conjugates |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
JP5475992B2 (en) * | 2005-08-19 | 2014-04-16 | エンドサイト,インコーポレイテッド | Multidrug ligand conjugate |
DK1928503T3 (en) | 2005-08-24 | 2012-10-15 | Immunogen Inc | Process for Preparation of Purified Drug Conjugates |
RS52060B (en) | 2006-01-25 | 2012-04-30 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
EP2044122B1 (en) * | 2006-07-18 | 2018-03-28 | Sanofi | Antagonist antibody against epha2 for the treatment of cancer |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
JP5537946B2 (en) | 2006-11-22 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR |
MX338185B (en) * | 2007-01-25 | 2016-04-05 | Dana Farber Cancer Inst Inc | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease. |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
US20080184892A1 (en) | 2007-02-06 | 2008-08-07 | Ctp Hydrogen Corporation | Architectures for electrochemical systems |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
AU2008224988A1 (en) | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
JP5618549B2 (en) * | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Method of treatment using EGFR antibody and SRC inhibitor and related preparation |
EP2139469A4 (en) * | 2007-03-19 | 2011-09-07 | Inflabloc Pharmaceuticals Inc | Cobalamin taxane bioconjugates |
CN104383553A (en) | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
ES2435779T3 (en) * | 2007-07-19 | 2013-12-23 | Sanofi | Cytotoxic agents comprising new tomaimycin derivatives and their therapeutic use |
CA2696360C (en) | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
EP2740490A1 (en) * | 2007-10-03 | 2014-06-11 | Cornell University | Treatment of proliferative disorders using antibodies to PSMA |
MX2010007102A (en) * | 2007-12-26 | 2011-07-01 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof. |
WO2009080831A1 (en) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
CA2710483C (en) * | 2007-12-26 | 2018-05-08 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells |
PL2238168T3 (en) * | 2007-12-26 | 2014-11-28 | Biotest Ag | Agents targeting cd138 and uses thereof |
DK2254571T3 (en) | 2008-03-18 | 2015-09-28 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and the chemotherapeutic agents and methods of using |
WO2009142773A2 (en) | 2008-05-22 | 2009-11-26 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
NZ594177A (en) | 2009-02-05 | 2014-02-28 | Immunogen Inc | Novel benzodiazepine derivatives |
ES2712732T3 (en) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Methods and kits for the diagnosis of cancer and the prediction of therapeutic value |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
AR078470A1 (en) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER |
KR20120080611A (en) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | Potent conjugates and hydrophilic linkers |
KR20130009760A (en) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Cd20 antibodies and uses thereof |
SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
CA3002192C (en) | 2010-03-26 | 2023-03-07 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
US9133239B2 (en) | 2010-04-20 | 2015-09-15 | The Research Foundation For The State University Of New York | Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration |
US9238690B2 (en) | 2010-10-29 | 2016-01-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
CN103298489A (en) | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | Novel EGFR-binding molecules and immunoconjugates thereof |
US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
SI3153504T1 (en) | 2010-12-09 | 2019-03-29 | Immunogen, Inc. | Methods for the preparation of charged crosslinkers |
US9433686B2 (en) | 2011-01-31 | 2016-09-06 | The Regents Of The University Of California | Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function |
KR20190089048A (en) | 2011-02-15 | 2019-07-29 | 이뮤노젠 아이엔씨 | Methods of preparation of conjugates |
KR20220123130A (en) | 2011-03-29 | 2022-09-05 | 이뮤노젠 아이엔씨 | Preparation of maytansinoid antibody conjugates by a one-step process |
SG193997A1 (en) | 2011-03-29 | 2013-11-29 | Immunogen Inc | Process for manufacturing conjugates of improved homogeneity |
PT2714733T (en) | 2011-05-21 | 2019-05-23 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
BR112013031819B1 (en) | 2011-06-10 | 2022-05-03 | Mersana Therapeutics, Inc | Polymeric support, pharmaceutical composition, compound and support use |
EA201792652A3 (en) | 2011-06-21 | 2018-09-28 | Иммуноджен, Инк. | NEW DERIVATIVES OF MAYTANZINOIDS WITH PEPTIDE LINKER AND THEIR CONJUGATES |
ES2806146T3 (en) | 2011-09-22 | 2021-02-16 | Amgen Inc | CD27L antigen-binding proteins |
CN104066481A (en) | 2011-11-21 | 2014-09-24 | 伊缪诺金公司 | Method of treatment of tumors that are resistant to EGFR therapies by EGFR antibody cytotoxic agent conjugate |
JP6218746B2 (en) | 2011-12-08 | 2017-10-25 | バイオテスト・アクチエンゲゼルシヤフト | Use of immune complexes targeting CD138 |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
UY34813A (en) | 2012-05-18 | 2013-11-29 | Amgen Inc | ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER |
CA2886993A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
KR20150070318A (en) | 2012-10-16 | 2015-06-24 | 엔도사이트, 인코포레이티드 | Drug delivery conjugates containing unnatural amino acids and methods for using |
TW201425336A (en) | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
JP6334553B2 (en) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス,インコーポレイティド | Protein-polymer-drug conjugate |
WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
US9920121B2 (en) | 2013-01-25 | 2018-03-20 | Amgen Inc. | Antibodies targeting CDH19 for melanoma |
AU2014273966B2 (en) | 2013-05-30 | 2017-08-31 | Kiniksa Pharmaceuticals, Ltd. | Oncostatin M receptor antigen binding proteins |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
KR102355745B1 (en) | 2013-10-11 | 2022-01-26 | 아사나 바이오사이언시스 엘엘씨 | Protein-polymer-drug conjugates |
CA2926586C (en) | 2013-10-11 | 2020-04-07 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
US9943606B2 (en) | 2014-01-15 | 2018-04-17 | Rutgers, The State University Of New Jersey | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents |
CN103804472B (en) * | 2014-01-23 | 2016-06-08 | 浙江大学 | A kind of taxone precursor |
EP3104880B1 (en) | 2014-02-14 | 2020-03-25 | MacroGenics, Inc. | Improved methods for the treatment of vascularizing cancers |
WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
US9669102B2 (en) | 2014-09-03 | 2017-06-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
SG10202008302XA (en) | 2014-12-04 | 2020-10-29 | Celgene Corp | Biomolecule conjugates |
US10722523B2 (en) | 2015-03-17 | 2020-07-28 | The Regents Of The University Of California | Chemoimmunotherapy for epithelial cancer |
US11066480B2 (en) | 2015-03-17 | 2021-07-20 | Memorial Sloan Kettering Cancer Center | Anti-MUC16 antibodies and uses thereof |
EP3280454A1 (en) | 2015-04-07 | 2018-02-14 | Memorial Sloan Kettering Cancer Center | Nanoparticle immunoconjugates |
CA2988806A1 (en) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Conjugates of cysteine engineered antibodies |
KR20180038461A (en) | 2015-07-21 | 2018-04-16 | 이뮤노젠 아이엔씨 | Method for preparing cytotoxic benzodiazepine derivatives |
WO2017025458A1 (en) | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
EP3356415A1 (en) | 2015-09-29 | 2018-08-08 | Amgen Inc. | Asgr inhibitors |
DK3380525T3 (en) | 2015-11-25 | 2024-01-29 | Immunogen Inc | PHARMACEUTICAL FORMULATIONS AND METHODS OF USING THEREOF |
TW201808336A (en) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | Treatment regimen using anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of tumors |
MA46887A (en) | 2016-11-23 | 2019-10-02 | Immunogen Inc | SELECTIVE SULPHONATION OF BENZODIAZEPINE DERIVATIVES |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
CN110366431B (en) | 2017-02-28 | 2023-07-18 | 伊缪诺金公司 | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
JP7320458B2 (en) | 2017-06-22 | 2023-08-03 | メルサナ セラピューティクス インコーポレイテッド | Methods of making drug-loaded polymer scaffolds and protein-polymer-drug conjugates |
WO2019133652A1 (en) | 2017-12-28 | 2019-07-04 | Immunogen, Inc. | Benzodiazepine derivatives |
KR20200123155A (en) | 2018-02-21 | 2020-10-28 | 셀진 코포레이션 | BCMA-binding antibodies and uses thereof |
JP2022513400A (en) | 2018-10-29 | 2022-02-07 | メルサナ セラピューティクス インコーポレイテッド | Cysteine-manipulated antibody with peptide-containing linker-drug conjugate |
CN114174340A (en) | 2019-03-20 | 2022-03-11 | 加利福尼亚大学董事会 | Encapsulated protein-6 antibodies and drug conjugates |
WO2020205564A1 (en) | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
RS64961B1 (en) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Camptothecin derivatives |
KR20220124762A (en) | 2020-01-09 | 2022-09-14 | 메르사나 테라퓨틱스, 인코포레이티드 | Site Specific Antibody-Drug Conjugates with Peptide-Containing Linkers |
BR112022017064A2 (en) | 2020-02-25 | 2022-11-16 | Mediboston Inc | CAMPTOTHECIN DERIVATIVES AND ITS CONJUGATES |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
WO2024023735A1 (en) | 2022-07-27 | 2024-02-01 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012624A2 (en) * | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
EP0624377A2 (en) * | 1993-05-14 | 1994-11-17 | Bristol-Myers Squibb Company | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1997044026A1 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
WO1998019705A1 (en) * | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
WO1999025729A1 (en) * | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
WO2000050059A1 (en) * | 1999-02-24 | 2000-08-31 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5399726A (en) * | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5646176A (en) * | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
US5824701A (en) * | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
US5663199A (en) * | 1994-11-30 | 1997-09-02 | Uniroyal Chemical Ltd./Ltee | Anti-viral aromatic O-alkylated oximes, ethers and thioethers |
US5811452A (en) | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
JP2003514903A (en) * | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | Taxane-containing cytotoxic drugs and their therapeutic use |
US6175023B1 (en) * | 2000-01-31 | 2001-01-16 | Jian Liu | Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III |
-
2000
- 2000-11-21 JP JP2001540081A patent/JP2003514903A/en active Pending
- 2000-11-21 EP EP00982077A patent/EP1242401B1/en not_active Expired - Lifetime
- 2000-11-21 WO PCT/US2000/030149 patent/WO2001038318A1/en active IP Right Grant
- 2000-11-21 DK DK00982077T patent/DK1242401T3/en active
- 2000-11-21 AU AU19149/01A patent/AU765588C/en not_active Ceased
- 2000-11-21 PT PT00982077T patent/PT1242401E/en unknown
- 2000-11-21 CA CA2388063A patent/CA2388063C/en not_active Expired - Fee Related
- 2000-11-21 DE DE60032633T patent/DE60032633T2/en not_active Expired - Lifetime
- 2000-11-21 ES ES00982077T patent/ES2276708T3/en not_active Expired - Lifetime
- 2000-11-21 NZ NZ517772A patent/NZ517772A/en unknown
- 2000-11-21 AT AT00982077T patent/ATE349438T1/en active
- 2000-11-22 US US09/717,026 patent/US6340701B1/en not_active Expired - Fee Related
-
2001
- 2001-08-21 US US09/933,018 patent/US6372738B2/en not_active Expired - Fee Related
-
2002
- 2002-01-30 US US10/059,022 patent/US6436931B1/en not_active Expired - Fee Related
- 2002-07-31 US US10/207,814 patent/US6706708B2/en not_active Expired - Fee Related
-
2003
- 2003-03-11 HK HK03101738.2A patent/HK1049997B/en not_active IP Right Cessation
- 2003-10-15 US US10/684,746 patent/US7008942B2/en not_active Expired - Fee Related
-
2005
- 2005-08-16 US US11/203,960 patent/US7217819B2/en not_active Expired - Fee Related
-
2006
- 2006-01-06 US US11/326,504 patent/US7528130B2/en not_active Expired - Fee Related
- 2006-01-13 US US11/331,045 patent/US7276499B2/en not_active Expired - Fee Related
-
2007
- 2007-04-18 US US11/785,483 patent/US7550609B2/en not_active Expired - Fee Related
- 2007-04-18 US US11/785,482 patent/US7476669B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/844,183 patent/US7585857B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012624A2 (en) * | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
EP0624377A2 (en) * | 1993-05-14 | 1994-11-17 | Bristol-Myers Squibb Company | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1997044026A1 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
WO1998019705A1 (en) * | 1996-11-05 | 1998-05-14 | Bristol-Myers Squibb Company | Branched peptide linkers |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
WO1999025729A1 (en) * | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
EP1033372A1 (en) * | 1997-11-18 | 2000-09-06 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
WO2000050059A1 (en) * | 1999-02-24 | 2000-08-31 | The Uab Research Foundation | Taxane derivatives for targeted therapy of cancer |
Non-Patent Citations (1)
Title |
---|
SAFAVY A ET AL: "PACLITAXEL DERIVATIVES FOR TARGETED THERAPY OF CANCER: TOWARD THE DEVELOPMENT OF SMART TAXANES", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 42, 1999, pages 4919 - 4924, XP000919106, ISSN: 0022-2623 * |
Cited By (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049672A3 (en) * | 2000-12-21 | 2003-01-03 | Univ Mcgill | Conjugates of antibodies and anticancer drugs |
WO2002049672A2 (en) * | 2000-12-21 | 2002-06-27 | Mcgill University | Conjugates of antibodies and anticancer drugs |
JP2005533026A (en) * | 2002-05-14 | 2005-11-04 | イミュノジェン・インコーポレーテッド | Cytotoxic agent containing taxane containing polyethylene glycol and therapeutic use thereof |
EP1534674A4 (en) * | 2002-08-02 | 2007-11-28 | Immunogen Inc | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
EP1534674A2 (en) * | 2002-08-02 | 2005-06-01 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7495114B2 (en) | 2002-08-02 | 2009-02-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
EP2341050A1 (en) * | 2002-08-02 | 2011-07-06 | ImmunoGen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7414073B2 (en) | 2002-08-02 | 2008-08-19 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
JP2006500364A (en) * | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | Crosslinkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
JP2011042675A (en) * | 2002-08-16 | 2011-03-03 | Immunogen Inc | Crosslinking agent with high reactivity and solubility, and use of the same in preparation of conjugate for use in targeted delivery of small molecule drug |
EP2281577A2 (en) | 2003-05-14 | 2011-02-09 | Immunogen, Inc. | Drug conjugate composition |
US7514080B2 (en) | 2003-05-14 | 2009-04-07 | Immunogen, Inc. | Drug conjugate composition |
US7374762B2 (en) | 2003-05-14 | 2008-05-20 | Immunogen, Inc. | Drug conjugate composition |
US7501120B2 (en) | 2003-05-14 | 2009-03-10 | Immunogen, Inc. | Drug conjugate composition |
US7494649B2 (en) | 2003-05-14 | 2009-02-24 | Immunogen, Inc. | Drug conjugate composition |
US8012485B2 (en) | 2003-05-14 | 2011-09-06 | Immunogen, Inc. | Drug conjugate composition |
EP1718335A4 (en) * | 2004-02-12 | 2010-11-10 | Univ New York State Res Found | Drug conjugates |
EP1718335A2 (en) * | 2004-02-12 | 2006-11-08 | The Research Foundation Of State University Of New York | Drug conjugates |
EP1688415A1 (en) * | 2004-12-07 | 2006-08-09 | Aventis Pharma S.A. | Cytotoxic agents comprising new C-2 modified taxanes |
US7598290B2 (en) | 2004-12-07 | 2009-10-06 | Immunogen, Inc. | Cytotoxic agents comprising new C-2 modified taxanes |
EA012625B1 (en) * | 2004-12-07 | 2009-10-30 | Авентис Фарма С.А. | Cytotoxic agents comprising new taxanes |
US7667054B2 (en) | 2004-12-07 | 2010-02-23 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
WO2006061259A3 (en) * | 2004-12-07 | 2007-01-11 | Aventis Pharma Sa | Cytotoxic agents comprising new c-2 modified taxanes |
WO2006061258A3 (en) * | 2004-12-07 | 2006-09-28 | Aventis Pharma Sa | Cytotoxic agents comprising new taxanes |
AU2005313444B2 (en) * | 2004-12-07 | 2011-11-10 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
WO2006061258A2 (en) * | 2004-12-07 | 2006-06-15 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
WO2006061259A2 (en) * | 2004-12-07 | 2006-06-15 | Aventis Pharma S.A. | Cytotoxic agents comprising new c-2 modified taxanes |
EP1669358A1 (en) * | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
EP2384767A1 (en) | 2005-03-24 | 2011-11-09 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
US9114179B2 (en) | 2005-08-03 | 2015-08-25 | Immunogen, Inc. | Immunoconjugate formulations |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
EP2241577A1 (en) | 2007-08-09 | 2010-10-20 | Boehringer Ingelheim International GmbH | Anti-CD37 antibodies |
EP2562187A1 (en) | 2007-08-09 | 2013-02-27 | Boehringer Ingelheim International GmbH | Anti-CD37 antibodies |
EP2278963A2 (en) * | 2008-01-16 | 2011-02-02 | Anwar Rayan | Derivatives of taxol and closely related compounds |
EP2278963A4 (en) * | 2008-01-16 | 2014-09-17 | Anwar Rayan | Derivatives of taxol and closely related compounds |
EP3266469A2 (en) | 2008-04-30 | 2018-01-10 | ImmunoGen, Inc. | Cross-linkers and their uses |
EP2998405A1 (en) | 2009-05-13 | 2016-03-23 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
EP3683317A2 (en) | 2009-05-13 | 2020-07-22 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
US8617554B2 (en) | 2009-05-13 | 2013-12-31 | Genzyme Corporation | Anti-human CD52 immunoglobulins |
US11945874B2 (en) | 2009-05-13 | 2024-04-02 | Genzyme Corporation | Anti-human CD52 immunoglobulins |
WO2010141566A1 (en) | 2009-06-03 | 2010-12-09 | Immunogen, Inc. | Conjugation methods |
EP3480202A1 (en) | 2009-06-03 | 2019-05-08 | ImmunoGen, Inc. | Conjugation methods |
EP3520816A2 (en) | 2009-10-23 | 2019-08-07 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
WO2013160396A1 (en) | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
WO2013171289A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with further agents |
WO2013171287A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
WO2013184514A1 (en) | 2012-06-04 | 2013-12-12 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
WO2014124316A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
EP3929217A2 (en) | 2013-02-08 | 2021-12-29 | Novartis AG | Specific sites for modifying antibodies to make immunoconjugates |
WO2014160160A2 (en) | 2013-03-13 | 2014-10-02 | Novartis Ag | Antibody drug conjugates |
WO2014151644A2 (en) | 2013-03-15 | 2014-09-25 | Genzyme Corporation | Anti-cd52 antibodies |
EP3514178A1 (en) | 2013-03-15 | 2019-07-24 | Novartis AG | Antibody drug conjugates |
US9708407B2 (en) | 2013-03-15 | 2017-07-18 | Genzyme Corporation | Anti-CD52 antibodies |
US10683314B2 (en) | 2014-02-28 | 2020-06-16 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
US10696700B2 (en) | 2014-02-28 | 2020-06-30 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
US10696699B2 (en) | 2014-02-28 | 2020-06-30 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
EP3960767A2 (en) | 2014-03-12 | 2022-03-02 | Novartis AG | Specific sites for modifying antibodies to make immunoconjugates |
WO2015138615A2 (en) | 2014-03-12 | 2015-09-17 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
WO2016203432A1 (en) | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US10328157B2 (en) | 2015-07-15 | 2019-06-25 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10293055B2 (en) | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US10232051B2 (en) | 2015-07-15 | 2019-03-19 | Hangzhou Dac Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
EP3888691A1 (en) | 2016-11-14 | 2021-10-06 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
WO2018142322A1 (en) | 2017-02-03 | 2018-08-09 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2019016772A2 (en) | 2017-07-21 | 2019-01-24 | Novartis Ag | Compositions and methods to treat cancer |
EP4085919A2 (en) | 2017-07-21 | 2022-11-09 | Novartis AG | Compositions and methods to treat cancer |
WO2020075817A1 (en) | 2018-10-10 | 2020-04-16 | 武田薬品工業株式会社 | Method for manufacturing antibody-drug conjugate |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
WO2020128612A2 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Antibodies to pmel17 and conjugates thereof |
WO2021220199A1 (en) | 2020-04-30 | 2021-11-04 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
EP3970752A1 (en) | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
WO2022058548A1 (en) | 2020-09-17 | 2022-03-24 | Merck Patent Gmbh | Molecules with solubility tag and related methods |
WO2022112942A2 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
WO2022221720A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU765588C (en) | Cytotoxic agents comprising taxanes and their therapeutic use | |
CA2485424C (en) | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use | |
US7495114B2 (en) | Cytotoxic agents containing novel potent taxanes and their therapeutic use | |
US7390898B2 (en) | Cytotoxic agents containing novel potent taxanes and their therapeutic use | |
JP2003531821A (en) | Cytotoxic drugs containing modified doxorubicin and daunorubicin and their therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 19149/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 517772 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000982077 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2388063 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 540081 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000982077 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 19149/01 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 517772 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 517772 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000982077 Country of ref document: EP |